Evidence map›Paper›PMID 35215301›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Pyrvinium Pamoate and Structural Analogs Are Early Macrofilaricide Leads.

Emma L Gunderson, Clifford Bryant, Christina A Bulman, Chelsea Fischer, Mona Luo, Ian Vogel, Kee-Chong Lim, Shabnam Jawahar, Nancy Tricoche, Denis Voronin and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Emma L GundersonDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Clifford BryantDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Christina A BulmanDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Chelsea FischerDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Mona LuoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Ian VogelDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Kee-Chong LimDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Shabnam JawaharMolecular Parasitology, New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.
Nancy TricocheMolecular Parasitology, New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.
Denis VoroninMolecular Parasitology, New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.
Christopher CorboDepartment of Biological Sciences, Wagner College, Staten Island, NY 10301, USA.
Rene B AyisehANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon.
Faustin P T ManfoANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon.
Glory E MbahANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon.
Fidelis Cho-NgwaANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon.
Brenda BeerntsenDepartment of Veterinary Pathobiology, University of Missouri-Columbia, Columbia, MO 65211, USA.
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
Sara LustigmanMolecular Parasitology, New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.ORCID 0000-0003-2389-6113
Judy A SakanariDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, USA.
University of California, San Francisco · USNew York Blood Center · USUniversity of Buea · CMUniversity of Missouri · USWagner College · US

Funding

Host-pathogen interactions in filarial worm infectionsZIAAI001322 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GHEDIN, ELODIE · 2020 to 2025
$6.7M
Novel Therapeutics for Treatment of River Blindness and Lymphatic FilariasisR21AI127639 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SAKANARI, JUDY · 2017 to 2018
$459k
NIH HHS R21AI127639
6 · The paper itself

Abstract

Onchocerciasis and lymphatic filariasis are neglected tropical diseases caused by infection with filarial worms. Annual or biannual mass drug administration with microfilaricidal drugs that kill the microfilarial stages of the parasites has helped reduce infection rates and thus prevent transmission of both infections. However, success depends on high population coverage that is maintained for the duration of the adult worm's lifespan. Given that these filarial worms can live up to 14 years in their human hosts, a macrofilaricidal drug would vastly accelerate elimination efforts. Here, we have evaluated the repurposed drug pyrvinium pamoate as well as newly synthesized analogs of pyrvinium for their efficacy against filarial worms in vitro and in vivo. We found that pyrvinium pamoate, tetrahydropyrvinium and one of the analogs were highly potent in inhibiting worms in in vitro whole-worm screening assays, and that all three compounds reduced female worm fecundity and inhibited embryogenesis in the

Indexed as

filarial diseasesmacrofilaricidespyrvinium pamoaterepurposed drugs

Identifiers

PMID35215301
PMCPMC8880385
OpenAlexW4210786722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.